ARx is Life Spine’s fourth 510(k) clearance in 2020 with 92 total since inception. The system is complemented by the PROLIFT® Expandable System and can be utilized with the SOLSTICE OCT System

FDA device

The US FDA’s Center for Devices and Radiological Health. (Credit: The U.S. Food and Drug Administration)

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market implant and instrument additions to the ARx Spinal System.

“The additions to the ARx Spinal System will allow us to provide surgeons with the tools to accommodate a larger range of complex and deformity spinal procedures,” said Rich Mueller, Chief Operating Officer for Life Spine. “The ARx Spinal System is designed to advance the treatment for spinal deformity patients with a range of unique spinal implants and intuitive instrumentation which is consistently being enhanced by our research and development team to meet patient needs.”

ARx is Life Spine’s fourth 510(k) clearance in 2020 with 92 total since inception. The system is complemented by the PROLIFT® Expandable System and can be utilized with the SOLSTICE® OCT System.

Life Spine is dedicated to improving the quality of life for spinal patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine, which is privately held, is based in Huntley, Illinois.

Source: Company Press Release